Gómez Rueda, Ana
Taus, Álvaro
Álvarez Álvarez, Rosa
Bernabé-Caro, Reyes
Chara, Luis
López-Brea, Marta
Vilà, Laia
Sala González, Maria Ángeles
del Barrio Díaz Aldagalán, Anabel
Esteban Herrera, Beatriz
López Castro, Rafael
Álvarez Cabellos, Ruth
Doménech, Marta
Falagan, Sandra
Moreno Vega, Alberto
Aguado, Carlos
Barba, Andrés
Delgado Ureña, Maria Teresa
Isla, Dolores
Bellido Hernández, Lorena
Fírvida Pérez, José Luis
Juan-Vidal, Óscar
Massutí, Bartomeu
Mielgo-Rubio, Xabier
Ortega, Ana Laura
Catot, Silvia
Dómine, Manuel
Escoín-Pérez, Corina
García Navalón, Francisco
Gil-Bazo, Ignacio
Muñoz, Silvia
Rodríguez-Abreu, Delvys
Villatoro Roldán, Rosa María
Alonso-Jáudenes Curbera, Guillermo
León-Mateos, Luis
Padilla, Airam
Paredes Lario, Alfredo
Sánchez-Torres, José Miguel
Garrido, Pilar http://orcid.org/0000-0002-5899-6125
,
Article History
Received: 8 November 2023
Accepted: 1 February 2024
First Online: 21 March 2024
Declarations
:
: AGR has received speaker and consultant honoraria from AstraZeneca, Amgen and Takeda, and travel support from AstraZeneca, Takeda and MSD; AT has received personal fees and non-financial support from Pfizer, Roche, BMS, MSD, and AstraZeneca; RAA has received consultant and speaker honoraria from Boehringer, Novartis, Pharmamar and Roche, conference registration support from MSD Oncology, and has participated as PI coordinator in projects sponsored by Boehringer, Cebiotex, Janssen Oncology, Novartis, Rain Therapeutics and Roche; RBC has received speaker and/or consultant honoraria from Pfizer, Janssen, Sanofi, AstraZeneca, Bristol Myers, Roche, Takeda and Jannsen, and research funding from Roche; LV has received consultant honorarium from Boehringer Ingelheim, AstraZeneca and Sanofi and speaker honoraria from AstraZeneca, Sanofi, MSD, Pfizer and Roche. MASG has received speaker and lecturer honoraria from Takeda and Roche, and travel/meeting attendance support from Roche and PharmaMar; MD has received grants from Roche and travel/meeting attendance support from Lilly; SF has received speaker honorarium from Pfizer and Sanofi, and travel support from AstraZeneca and MSD; CA has received consultant honorarium from AstraZeneca, BMS, MSD and Novartis, research funding from MSD, Mirati and AstraZeneca, and travel support from Roche, Novartis, Takeda and Pierre Fabre; AB has received speaker and consultant honoraria from BMS, Roche, MSD, Sanofi and Takeda, and travel support from MSD, Roche and BMS; DI has received speaker/consultant honoraria from Amgen, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Hoffmann-La Roche, Janssen, Lilly, Merck, MSD, Novartis, Pfizer, Sanofi and Takeda, has participated in clinical trials sponsored by Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Daiichi Sankyo, Hoffmann-La Roche, GSK, Janssen, Lilly, Merck, Mirati Therapeutics, MSD, Novartis, Pfizer and Sanofi, and has received research grants from AstraZeneca, BMS, Hoffmann-La Roche and GSK; LBH has received speaker honorarium from Roche, BMS and AstraZeneca, consultant honorarium from Boehringer and Sanofi, and meeting attendance support from MSD, Novartis, Sanofi and AstraZeneca; JLFP has received consultant and speaker honoraria from AstraZeneca; BM has received personal fees from Roche, BMS, MSD, Boehringer Ingelheim and Pfizer; XMR has received speaker and/or consultant honoraria from Novartis, Roche, Pfizer, Astra Zeneca and MSD, grants from BMS, travel/meeting attendance support from Roche, Lilly and MSD, and declares his membership of the boards of the Spanish Group for Transversal Oncology and Research in Orphan and Infrequent Tumors (GETTHI) and the Spanish Group for Cancer Immuno-Biotherapy (GETICA); MD has received consultant and/or speaker honoraria from AstraZeneca, Boehringer Ingelheim, Janssen Cilag, BMS MSD, Pfizer, Roche, Sanofi and Takeda; IGB has received consultant and/or speaker honoraria from MSD Oncology, Lilly, AstraZeneca and BMS/Celgene, Roche and Amgen, and travel support from MSD Oncology, Lilly and Daiichi Sankyo; DR-A has received consultant and speaker honoraria from Roche/Genentech, AstraZeneca, BMS, Boehringer Ingelheim, MSD, Merck Serono, Eli Lilly, Gilead, Sanofi, Regeneron, Incyte, Pfizer, Takeda and Novartis, and travel support from Roche, BMS, MSD, Sanofi, Regeneron and Novartis; GAJC has received speaker/consultant honoraria from AstraZeneca and Roche; LLM has received consultant/speaker honoraria from AstraZeneca; JMST has received speaker/consultant honoraria from AstraZeneca; PG has received consultant honorarium from Abbvie, Amgen, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Daiichi Sankyo, GlaxoSmithKline, Janssen, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi and Takeda, and direct funding from Medscape and Touch Medical. All other authors have no conflict of interest to declare.
: This study followed the Helsinki Declaration, Good Clinical Practices and the Spanish Organic Law 3/2018 of 5 December on the Protection of Personal Data and digital rights guarantee. The study was approved by the Ethics Committee of Hospital Puerta de Hierro de Majadahonda (Madrid). Written informed consent was obtained from all enrolled patients. Patient medical information obtained for this study was confidential and was only disclosed to the researchers and third parties involved, as detailed in the informed consent form signed by the patients. Confidentiality standards were maintained by assigning each patient a unique subject identification number.